Guggenheim Raises Apogee Therapeutics PT to $160, Maintains Buy Rating

Tuesday, Mar 24, 2026 7:47 am ET1min read
APGE--

Guggenheim Raises Apogee Therapeutics PT to $160, Maintains Buy Rating

Guggenheim Raises Apogee Therapeutics PT to $160, Maintains Buy Rating

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet